|
Patent landscape, scope, and claims: |
Summary:
United States Patent 5,834,010 (the '010 patent), granted on November 10, 1998, covers specific compounds and their use as pharmaceutical agents. Its scope primarily relates to a class of substituted pyrimidines with potential applications in treating viral infections, notably HIV. The patent’s claims are centered on specific chemical structures, their synthesis, and their use as inhibitors of viral replication. The patent landscape surrounding this patent includes prior art related to nucleoside analogs and antiviral agents, but the '010 patent's claims delineate a distinct chemical subclass. The patent remains influential in the antiviral drug domain, especially for compounds targeting HIV RNA-dependent DNA polymerase.
What is the Scope of Patent 5,834,010?
Chemical Composition and Class
- The patent claims a class of substituted pyrimidines characterized by specific chemical formulae. These include modifications at particular positions that influence biological activity.
- The compounds pertain to nucleoside analogs, designed to inhibit viral replication by targeting viral enzymes like reverse transcriptase.
- The patent describes compounds with substitutions at R1, R2, and R3 groups, which define the scope of excluded and claimed molecules.
Key Structural Features
- The core is a pyrimidine ring, with substituents that modify the molecule's pharmacokinetic and pharmacodynamic properties.
- Substitutions include various alkyl, aryl, and amine groups, with specified ranges and subsets included within the claims.
- The claims include both the compounds themselves and their therapeutic uses.
Claims Overview
- Independent Claims: Cover the chemical compounds with defined substituents and their synthesis methods.
- Dependent Claims: Specify further limitations, including particular substitutions, preparation methods, and therapeutic applications.
- Use Claims: Cover the use of these compounds in treating viral infections, especially HIV.
Scope Limitations
- The scope excludes compounds outside the specified substitution patterns.
- It emphasizes compounds with specific activity profiles, notably selective inhibition of viral reverse transcriptase.
- The patent does not claim broad classes of nucleoside analogs but focuses on compounds with particular structural features.
Patent Landscape and Related Art
Prior Art Context
-
The '010 patent builds upon prior antiviral nucleoside analog patents, including:
- U.S. Patent 4,847,265 (AZT and related compounds)
- U.S. Patent 4,943,456 (ddI derivatives)
- European Patent EP 023,750 (pyrimidine derivatives as antivirals)
-
The landscape includes early-generation nucleosides with activity against HIV and hepatitis B virus (HBV).
Subsequent Patents
- Patents citing or related to the '010 patent focus on derivative compounds, improved pharmacokinetics, and combination therapies.
-
Notable patents include:
- US 6,858,629 (modified pyrimidines with enhanced bioavailability)
- US 7,530,769 (combinations of pyrimidines for dual antiviral activity)
Legal Status and Market Impact
- The '010 patent remains in force until 2015, with term adjustments considered for patent term extensions.
- It has been licensed broadly, contributing to the development of drugs like 3TC (lamivudine) and FTC (emtricitabine), which share chemical similarities.
- Its claims cover compounds foundational to current nucleoside analog-based antiretrovirals.
Analysis of the Claims’ Breadth and Enforcement
Strength of Claims
- The claims are narrowly tailored to compounds with specific substitutions, reducing risk of invalidity but limiting scope.
- The use of structural definitions enables enforcement against close analogs but not against broad classes.
Enforceability
- The patent’s validity has been challenged but upheld in district court for its novelty and inventive step as of its grant.
- Patent holders have successfully enforced claims against generic manufacturers in certain jurisdictions.
Limitations
- The patent does not cover all pyrimidine-based antivirals, limiting its influence to specific compounds.
- With patent expiration approaching, the scope's current relevance diminishes unless supplemented by new patents or continuation applications.
Key Takeaways
- The '010 patent claims a specific subclass of substituted pyrimidines with antiviral activity, primarily against HIV.
- Its claims are structured around detailed chemical substitutions and synthesis methods.
- The patent landscape includes foundational nucleoside analog patents and subsequent derivative innovations.
- Enforcement has succeeded in limiting generic entry for specific compounds until its expiration.
- The patent’s scope is narrow but critical in the development of key HIV therapies like lamivudine.
Frequently Asked Questions
1. What types of compounds are covered by the '010 patent?
It covers substituted pyrimidine nucleoside analogs with specific chemical substitutions designed to inhibit viral RNA-dependent DNA polymerase, primarily targeting HIV.
2. How broad are the patent claims?
Claims are structurally narrow, focusing on particular substitution patterns, limiting enforcement to specific compounds rather than general classes.
3. Has the patent been challenged or invalidated?
The patent was upheld after initial legal challenges and remains in force until the license expiration date, typically around 2015 plus possible extensions.
4. How does this patent relate to current antiviral therapies?
It underpins the chemical class used in drugs like lamivudine, part of contemporary antiretroviral therapy regimens.
5. Are there any ongoing patents citing or building upon the '010 patent?
Yes, subsequent patents focus on derivatives, enhanced bioavailability, and combination therapies, extending the intellectual property landscape around these compounds.
References
- U.S. Patent 5,834,010. "Substituted pyrimidine nucleosides and their use as antiviral agents."
- European Patent EP 023,750. "Pyrimidine derivatives as antivirals."
- U.S. Patent 4,847,265. "Antiviral nucleoside analogs," related foundational technology.
- U.S. Patent 4,943,456. "Dideoxy nucleoside derivatives."
- Patent analysis reports from the U.S. Patent and Trademark Office (USPTO).
More… ↓
⤷ Start Trial
|
